Mhc universal cells survive in an allogeneic environment after incompatible transplantation

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Figueiredo, Constança ^a   Wedekind, Dirk ^a   Müller, Thomas ^a   Vahlsing, Stefanie ^a   Horn, Peter A ^b   Seltsam, Axel ^a,c   Blasczyk, Rainer ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c Institute Springe   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; GAMMA INTERFERON; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; LENTIVIRUS VECTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; HISTOCOMPATIBILITY ANTIGEN; HISTOCOMPATIBILITY ANTIGENS RT, RAT;

ADULT ANIMAL; ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; ENGRAFTMENT; EXPERIMENTAL TRANSPLANTATION; FIBROBLAST; FIBROSARCOMA; GENE SILENCING; GENE TARGETING; GENE THERAPY; GENETIC TRANSDUCTION; GRAFT REJECTION; HAPLOTYPE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MIXED LYMPHOCYTE REACTION; NATURAL KILLER CELL; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; T LYMPHOCYTE; TARGET CELL; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BLOOD; CELL PROLIFERATION; GRAFT SURVIVAL; IMMUNOLOGY; LEWIS RAT; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; FIBROBLASTS; GRAFT SURVIVAL; HISTOCOMPATIBILITY ANTIGENS; KILLER CELLS, NATURAL; MAJOR HISTOCOMPATIBILITY COMPLEX; RATS; RATS, INBRED LEW; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84888633460     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/796046     Document Type: Article

References (45)

1. Orlando G., Baptista P., Birchall M., de Coppi P., Farney A., Guimaraes-Souza N. K., Opara E., Rogers J., Seliktar D., Shapira-Schweitzer K., Stratta R. J., Atala A., Wood K. J., Soker S., Regenerative medicine as applied to solid organ transplantation: current status and future challenges. Transplant International 2011 24 3 223 232 2-s2.0-79551525410 10.1111/j.1432-2277.2010. 01182.x
2. Boyd A. S., Fairchild P. J., Approaches for immunological tolerance induction to stem cell-derived cell replacement therapies. Expert Review of Clinical Immunology 2010 6 3 435 448 2-s2.0-77952072848 10.1586/eci.10.20
3. Park I., Arora N., Huo H., Maherali N., Ahfeldt T., Shimamura A., Lensch M. W., Cowan C., Hochedlinger K., Daley G. Q., Disease-specific induced pluripotent stem cells. Cell 2008 134 5 877 886 2-s2.0-50549089957 10.1016/j.cell.2008.07.041
4. Smith D., Commercialization challenges associated with induced pluripotent stem cell-based products. Regenerative Medicine 2010 5 4 593 603 2-s2.0-77954805151 10.2217/rme.10.50
5. Zhao T., Zhang Z., Rong Z., Xu Y., Immunogenicity of induced pluripotent stem cells. Nature 2011 474 7350 212 215 2-s2.0-79957807595 10.1038/nature10135
6. Fernandez-Vina M. A., Klein J. P., Haagenson M., Spellman S. R., Anasetti C., Noreen H., Baxter-Lowe L. A., Cano P., Flomenberg N., Confer D. L., Horowitz M. M., Oudshoorn M., Petersdorf E. W., Setterholm M., Champlin R., Lee S. J., de Lima M., Multiple mismatches at the low expression HLA loci DP, DQ, and DRB3/4/5 associate with adverse outcomes in hematopoietic stem cell transplantation. Blood 2013 121 22 4603 4610 10.1182/blood-2013-02-481945
7. Uchiyama H., Kayashima H., Matono R., Shirabe K., Yoshizumi T., Ikegami T., Soejima Y., Matsuura T., Taguchi T., Maehara Y., Relevance of HLA compatibility in living donor liver transplantation: the double-edged sword associated with the patient outcome. Clinical Transplantation 2012 26 5 E522 E529 10.1111/ctr.12019
8. Binkowski T. A., Marino S. R., Joachimiak A., Predicting HLA class I non-permissive amino acid residues substitutions. PLoS ONE 2012 7 8 e41710 10.1371/journal.pone.0041710
9. Ciurea S. O., Thall P. F., Wang X., Wang S. A., Hu Y., Cano P., Aung F., Rondon G., Molldrem J. J., Korbling M., Shpall E. J., de Lima M., Champlin R. E., Fernandez-Vina M., Donor-specific anti-HLAAbs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood 2011 118 22 5957 5964 2-s2.0-82155184523 10.1182/blood-2011-06-362111
10. Higgins R., Lowe D., Hathaway M., Williams C., Lam F. T., Kashi H., Tan L. C., Imray C., Fletcher S., Chen K., Krishnan N., Hamer R., Daga S., Edey M., Zehnder D., Briggs D., Human leukocyte antigen antibody-incompatible renal transplantation: excellent medium-term outcomes with negative cytotoxic crossmatch. Transplantation 2011 92 8 900 906 2-s2.0-80054742066 10.1097/TP.0b013e31822dc38d
11. Susal C., Roelen D. L., Fischer G., Campos E. F., Gerbase-Delima M., Honger G., Schaub S., Lachmann N., Martorell J., Claas F., Algorithms for the determination of unacceptable HLA antigen mismatches in kidney transplant recipients. Tissue Antigens 2013 82 2 83 92 10.1111/tan.12137
12. Davidson B. L., McCray P. B., Current prospects for RNA interference-based therapies. Nature Reviews Genetics 2011 12 5 329 340 2-s2.0-79954580272 10.1038/nrg2968
13. Elbashir S. M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T., Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001 411 6836 494 498 2-s2.0-0035942736 10.1038/35078107 (Pubitemid 32494397)
14. Gu Y., Hou W., Xu C., Li S., Shih J. W. K., Xia N., The enhancement of RNAi against HIV in vitro and in vivo using H-2K(k) protein as a sorting method. Journal of Virological Methods 2012 182 1-2 9 17 2-s2.0-84859984433 10.1016/j.jviromet.2012.02.007
15. Gillissen B., Richter A., Richter A., Overkamp T., Essmann F., Hemmati P. G., Preissner R., Belka C., Daniel P. T., Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent "type I" mode. Cell Death and Disease 2013 4 article e643 10.1038/cddis.2013.67
16. Ma J. F., Liu L., Yang W. J., Zang L. N., Xi Y. M., RNAi-mediated knockdown of relaxin decreases in vitro proliferation and invasiveness of osteosarcoma MG-63 cells by inhibition of MMP-9. European Review for Medical and Pharmacological Sciences 2013 17 8 1102 1109
17. Raoul C., Barker S. D., Aebischer P., Viral-based modelling and correction of neurodegenerative diseases by RNA interference. Gene Therapy 2006 13 6 487 495 2-s2.0-33645165026 10.1038/sj.gt.3302690
18. Hou Y., Xing L., Fu S., Zhang X., Liu J., Liu H., Lv B., Cui H., Down-regulation of inducible co-stimulator (ICOS) by intravitreal injection of small interfering RNA (siRNA) plasmid suppresses ongoing experimental autoimmune uveoretinitis in rats. Graefe's Archive for Clinical and Experimental Ophthalmology 2009 247 6 755 765 2-s2.0-67349102674 10.1007/s00417-008-1023-0
19. McCaskill J., Singhania R., Burgess M., Allavena R., Wu S., Blumenthal A., McMillan N. A., Efficient biodistribution and gene silencing in the lung epithelium via intravenous liposomal delivery of siRNA. Molecular Therapy-Nucleic Acids 2013 2 article e96 10.1038/mtna.2013.22
20. Presumey J., Salzano G., Courties G., Shires M., Ponchel F., Jorgensen C., Apparailly F., de Rosa G., PLGA microspheres encapsulating siRNA anti-TNF α: efficient RNAi-mediated treatment of arthritic joints. European Journal of Pharmaceutics and Biopharmaceutics 2012 82 3 457 464 10.1016/j.ejpb.2012.07. 021
21. Figueiredo C., Goudeva L., Horn P. A., Eiz-Vesper B., Blasczyk R., Seltsam A., Generation of HLA-deficient platelets from hematopoietic progenitor cells. Transfusion 2010 50 8 1690 1701 2-s2.0-77955168172 10.1111/j.1537-2995. 2010.02644.x
22. Figueiredo C., Seltsam A., Blasczyk R., Class-, gene-, and group-specific HLA silencing by lentiviral shRNA delivery. Journal of Molecular Medicine 2006 84 5 425 437 2-s2.0-33646369190 10.1007/s00109-005-0024-2 (Pubitemid 43673617)
23. Jaimes Y., Seltsam A., Eiz-Vesper B., Blasczyk R., Figueiredo C., Regulation of HLA class II expression prevents allogeneic T-cell responses. Tissue Antigens 2011 77 1 36 44 2-s2.0-78650000599 10.1111/j.1399-0039.2010. 01576.x
24. Riolobos L., Hirata R. K., Turtle C. J., Wang P. R., Gornalusse G. G., Zavajlevski M., Riddell S. R., Russell D. W., HLA engineering of human pluripotent stem cells. Molecular Therapy 2013 21 1232 1241 10.1038/mt.2013.59
25. Dressel R., Walter L., Günther E., Genomic and functional aspects of the rat MHC, the RT1 complex. Immunological Reviews 2001 184 82 95 2-s2.0-0035552452 10.1034/j.1600-065x.2001.1840108.x (Pubitemid 34123766)
26. Figueiredo C., Wittmann M., Wang D., Dressel R., Seltsam A., Blasczyk R., Eiz-Vesper B., Heat shock protein 70(HSP70) induces cytotoxicity of T-helper cells. Blood 2009 113 13 3008 3016 2-s2.0-63849213897 10.1182/blood-2008-06- 162727
27. Einecke G., Sis B., Reeve J., Mengel M., Campbell P. M., Hidalgo L. G., Kaplan B., Halloran P. F., Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. The American Journal of Transplantation 2009 9 11 2520 2531 2-s2.0-70350131760 10.1111/j.1600-6143.2009. 02799.x
28. Ishii D., Schenk A. D., Baba S., Fairchild R. L., Role of TNF α in early chemokine production and leukocyte infiltration into heart allografts. The American Journal of Transplantation 2010 10 1 59 68 2-s2.0-72549116180 10.1111/j.1600-6143.2009.02921.x
29. Wang H., Guan Q., Lan Z., Li S., Ge W., Chen H., Nguan C. Y. C., Du C., Prolonged renal allograft survival by donor interleukin-6 deficiency: association with decreased alloantibodies and increased intragraft T regulatory cells. The American Journal of Physiology-Renal Physiology 2012 302 2 F276 F283 2-s2.0-84855320825 10.1152/ajprenal.00258.2011
30. Hummel M., Kurian S. M., Lin S., Borodyanskiy A., Zhang Z., Li Z., Kim S. J., Salomon D. R., Abecassis M., Intragraft TNF receptor signaling contributes to activation of innate and adaptive immunity in a renal allograft model. Transplantation 2009 87 2 178 188 2-s2.0-59649108625 10.1097/TP.0b013e3181938971
31. Ashokkumar C., Shapiro R., Tan H., Ningappa M., Elinoff B., Fedorek S., Sun Q., Higgs B. W., Randhawa P., Humar A., Sindhi R., Allospecific CD154+ T-cytotoxic memory cells identify recipients experiencing acute cellular rejection after renal transplantation. Transplantation 2011 92 4 433 438 2-s2.0-80051799877 10.1097/TP.0b013e318225276d
32. Kreijveld E., Koenen H. J. P. M., van Cranenbroek B., van Rijssen E., Joosten I., Hilbrands L. B., Immunological monitoring of renal transplant recipients to predict acute allograft rejection following the discontinuation of tacrolimus. PLoS ONE 2008 3 7 2-s2.0-50549084327 10.1371/journal.pone.0002711 e2711
33. Maehr R., Chen S., Snitow M., Ludwig T., Yagasaki L., Goland R., Leibel R. L., Melton D. A., Generation of pluripotent stem cells from patients with type 1 diabetes. Proceedings of the National Academy of Sciences of the United States of America 2009 106 37 15768 15773 2-s2.0-70349437501 10.1073/pnas.0906894106
34. van Hoof D., D'Amour K. A., German M. S., Derivation of insulin-producing cells from human embryonic stem cells. Stem Cell Research 2009 3 2-3 73 87 2-s2.0-70349863066 10.1016/j.scr.2009.08.003
35. Sheridan S. D., Theriault K. M., Reis S. A., Zhou F., Madison J. M., Daheron L., Loring J. F., Haggarty S. J., Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome. PLoS ONE 2011 6 10 2-s2.0-80053948646 10.1371/journal.pone.0026203 e26203
36. Urbach A., Bar-Nur O., Daley G. Q., Benvenisty N., Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell 2010 6 5 407 411 2-s2.0-77956214743 10.1016/j.stem.2010. 04.005
37. Kieran N., Wang X., Perkins J., Davis C., Kendrick E., Bakthavatsalam R., Dunbar N., Warner P., Nelson K., Smith K. D., Nicosia R. F., Alpers C. E., Leca N., Kowalewska J., Combination of peritubular C4d and transplant glomerulopathy predicts late renal allograft failure. Journal of the American Society of Nephrology 2009 20 10 2260 2268 2-s2.0-70349923502 10.1681/ASN.2009020199
38. Cosio F. G., Gloor J. M., Sethi S., Stegall M. D., Transplant glomerulopathy. The American Journal of Transplantation 2008 8 3 492 496 2-s2.0-39649115166 10.1111/j.1600-6143.2007.02104.x (Pubitemid 351287536)
39. Kohei N., Tanabe T., Horita S., Omoto K., Ishida H., Yamaguchi Y., Tanabe K., Sequential analysis of donor-specific antibodies and pathological findings in acute antibody-mediated rejection in a rat renal transplantation model. Kidney International 2013 10.1038/ki.2013.117
40. Raulet D. H., Vance R. E., Self-tolerance of natural killer cells. Nature Reviews Immunology 2006 6 7 520 531 2-s2.0-33745567831 10.1038/nri1863 (Pubitemid 43980524)
41. Karre K., Ljunggren H. G., Piontek G., Kiessling R., Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986 319 6055 675 678 2-s2.0-0022616253 (Pubitemid 16119452)
42. Wanderer A. A., Rationale and timeliness for IL-1 β -targeted therapy to reduce allogeneic organ injury at procurement and to diminish risk of rejection after transplantation. Clinical Transplantation 2010 24 3 307 311 2-s2.0-77954155781 10.1111/j.1399-0012.2010.01256.x
43. Vamvakopoulos J. E., Taylor C. J., Green C., McNeil K., Wallwork J., Goodman R., Metcalfe S. M., Interleukin 1 and chronic rejection: possible genetic links in human heart allografts. The American Journal of Transplantation 2002 2 1 76 83 2-s2.0-0036460891 10.1034/j.1600-6143.2002.020113.x (Pubitemid 36306810)
44. Masopust D., Vezys V., Marzo A. L., Lefrançois L., Preferential localization of effector memory cells in nonlymphoid tissue. Science 2001 291 5512 2413 2417 2-s2.0-0035937587 10.1126/science.1058867 (Pubitemid 32231804)
45. Ortiz Y. M., Arias L. F., Alvarez C. M., Garcia L. F., Memory phenotype and polyfunctional T cells in kidney transplant patients. Transplant Immunology 2013 28 2-3 127 137 10.1016/j.trim.2013.02.003